IRWD

We rate IRONWOOD PHARMACEUTICALS INC (IRWD) as a Hold with a composite score of 62.6/100 at a current price of $3.82. The stock presents a mixed quantitative picture — neither compelling enough to warrant new accumulation nor weak enough to justify selling for existing holders. Our factors are split, and the overall profile suggests patience is warranted.

The rating is primarily driven by strength in value (95th percentile) and momentum (87th percentile), which together account for the majority of the composite score. Offsetting weakness in stability (32th percentile) and investment (38th percentile) tempers our overall conviction. We assign a Wide Moat rating (72/100), High uncertainty, and Poor capital allocation.

Key items to watch: sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.

IRONWOOD PHARMACEUTICALS INC holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 62.6/100 places it at rank #453 in our full 7,333-stock universe. At $213M in market capitalization, IRONWOOD PHARMACEUTICALS INC is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.

The near-term outlook is constructive, with revenue growing at 29% and momentum in the 87th percentile confirming positive market sentiment and institutional accumulation. The combination of strong top-line growth and favorable price dynamics suggests the company is executing well on its growth strategy. Investment factor at the 38th percentile indicates reinvestment patterns that investors should monitor for sustainability.

The margin cascade tells an important story: gross margins of 100% (+57.5pp vs sector) narrow to operating margins of 18% (+16.8pp vs sector) and net margins of -6.6%, yielding a gross-to-net conversion rate of -7%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.

At a current price of $3.82, IRONWOOD PHARMACEUTICALS INC appears undervalued relative to its fundamentals. Our value factor score of 95/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The stock screens as attractively priced on a majority of these measures, suggesting the market may be underappreciating the underlying fundamentals.

The stock currently trades at a P/E of 21.5x (roughly in line with the sector median of 22.3x), EV/EBITDA of 7.2x (discounted to peers), P/S of 1.9x. The below-sector P/E suggests possible undervaluation or the market pricing in near-term headwinds.

We assign a High uncertainty rating to IRONWOOD PHARMACEUTICALS INC. Key risk factors include current negative profitability (net margin -6.6%), below-average price stability (32th percentile). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.

Specific risk factors that inform our assessment include: current negative profitability (net margin -6.6%); below-average price stability (32th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 32th percentile and quality factor at the 66th percentile provide a quantitative summary of the overall risk landscape.

Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.

We rate IRONWOOD PHARMACEUTICALS INC's capital allocation as Poor. Key concerns include low returns on equity (-41.4%), negative profitability. Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — IRONWOOD PHARMACEUTICALS INC significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.

Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.

In summary, IRONWOOD PHARMACEUTICALS INC receives a Hold rating with a composite score of 62.6/100 (rank #453 of 7,333). Our quantitative framework assigns a Wide Moat (72/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 64/100.

Our analysis supports a neutral stance on IRONWOOD PHARMACEUTICALS INC. While the quantitative profile is not weak enough to warrant selling, it lacks the multi-factor strength required for a buy recommendation. Existing holders should maintain positions and monitor for catalysts — either fundamental improvement or valuation compression — that would shift the risk-reward balance.